Association between obstructive sleep apnoea and cancer: a cross-sectional, population-based study of the DISCOVERY cohort.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
03 03 2023
Historique:
entrez: 3 3 2023
pubmed: 4 3 2023
medline: 8 3 2023
Statut: epublish

Résumé

Nocturnal hypoxia in obstructive sleep apnoea (OSA) is a potential risk factor for cancer. We aimed to investigate the association between OSA measures and cancer prevalence in a large national patient cohort. Cross-sectional study. 44 sleep centres in Sweden. 62 811 patients from the Swedish registry for positive airway pressure (PAP) treatment in OSA, linked to the national cancer registry and national socioeconomic data (the course of DIsease in patients reported to Swedish CPAP, Oxygen and VEntilator RegistrY cohort). After propensity score matching for relevant confounders (anthropometric data, comorbidities, socioeconomic status, smoking prevalence), sleep apnoea severity, measured as Apnoea-Hypopnoea Index (AHI) or Oxygen Desaturation Index (ODI), were compared between those with and without cancer diagnosis up to 5 years prior to PAP initiation. Subgroup analysis for cancer subtype was performed. OSA patients with cancer (n=2093) (29.8% females, age 65.3 (SD 10.1) years, body mass index 30 (IQR 27-34) kg/m OSA mediated intermittent hypoxia was independently associated with cancer prevalence in this large, national cohort. Future longitudinal studies are warranted to study the potential protective influence of OSA treatment on cancer incidence.

Identifiants

pubmed: 36868588
pii: bmjopen-2022-064501
doi: 10.1136/bmjopen-2022-064501
pmc: PMC9990651
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e064501

Informations de copyright

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Am J Respir Crit Care Med. 2012 Jul 15;186(2):190-4
pubmed: 22610391
Eur Respir J. 2019 Jun 20;53(6):
pubmed: 31109987
Sleep Med. 2014 Sep;15(9):1016-20
pubmed: 25085620
Scand J Public Health. 2021 Jun;49(4):377-383
pubmed: 32349623
JAMA. 2003 May 7;289(17):2230-7
pubmed: 12734134
Eur J Epidemiol. 2019 Apr;34(4):423-437
pubmed: 30929112
Multivariate Behav Res. 2011 May;46(3):399-424
pubmed: 21818162
Sleep Med. 2012 Dec;13(10):1254-60
pubmed: 23149216
Rev Endocr Metab Disord. 2015 Mar;16(1):25-34
pubmed: 25502450
CMAJ. 2014 Sep 16;186(13):985-92
pubmed: 25096668
Eur J Epidemiol. 2009;24(11):659-67
pubmed: 19504049
Chest. 2020 Dec;158(6):2610-2620
pubmed: 32629036
Acta Oncol. 2009;48(1):27-33
pubmed: 18767000
BMJ Open. 2021 Feb 11;11(2):e042323
pubmed: 33574148
Front Immunol. 2012 Jan 12;2:98
pubmed: 22566887
PLoS One. 2021 Apr 7;16(4):e0249099
pubmed: 33826649
Ann Am Thorac Soc. 2022 Mar;19(3):469-475
pubmed: 34792438
Sci Rep. 2019 Dec 13;9(1):19044
pubmed: 31836779
ERJ Open Res. 2021 Jan 18;7(1):
pubmed: 33532458
Chest. 2015 Nov;148(5):1140-1147
pubmed: 26020135
Nat Rev Endocrinol. 2014 Aug;10(8):455-465
pubmed: 24935119
BMC Cancer. 2019 Feb 13;19(1):146
pubmed: 30760242
Respir Res. 2018 Feb 12;19(1):28
pubmed: 29433520
Sleep. 2013 Oct 01;36(10):1429-35
pubmed: 24082302
Int J Mol Sci. 2019 Jan 22;20(3):
pubmed: 30678164
Acta Oncol. 2018 Apr;57(4):440-455
pubmed: 29226751
J Clin Sleep Med. 2022 May 1;18(5):1427-1440
pubmed: 34755597
BMJ Open. 2020 Nov 19;10(11):e040396
pubmed: 33444200
Sleep Med. 2021 Dec;88:274-281
pubmed: 34219029
Ann Am Thorac Soc. 2019 Jan;16(1):22-28
pubmed: 30230362
Am J Respir Crit Care Med. 2013 Jan 1;187(1):99-105
pubmed: 23155146
Chest. 2018 Dec;154(6):1348-1358
pubmed: 30059679
Medicine (Baltimore). 2021 Feb 12;100(6):e24659
pubmed: 33578596
BMC Public Health. 2011 Jun 09;11:450
pubmed: 21658213
PLoS One. 2012;7(2):e30905
pubmed: 22363512
Sleep Med. 2014 Jul;15(7):749-54
pubmed: 24891080
Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):726-35
pubmed: 16897791

Auteurs

Andreas Palm (A)

Department of Medical Sciences, Lung, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden andreas.palm@medsci.uu.se.
Centre for Research and Development, Region of Gävleborg Gävle Hospital, Gävle, Sweden.

J Theorell-Haglöw (J)

Department of Medical Sciences, Lung, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.

Johan Isakson (J)

Centre for Research and Development, Region of Gävleborg, Gävle Hospital, Gävle, Sweden.

Mirjam Ljunggren (M)

Department of Medical Sciences, Lung, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.

Josefin Sundh (J)

Department of Respiratory Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.

Magnus Per Ekström (MP)

Department of Clinical Sciences, Respiratory Medicine and Allergology, Lund University, Lund, Sweden, Lund, Sweden.

Ludger Grote (L)

Sahlgrenska Academy, Gothenburg University, Centre for Sleep and Wake Disorders, Goteborg, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH